About this trial
Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18
Confirmed diagnosis of autoimmune MG
Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
Signed consent form
Disqualifiers
Known Pregnancy
Known respiratory disorder (other than MG)
Recent (within past 4 weeks) respiratory infection
Current MG crisis or exacerbation (necessitating increase in MG medication &/or hospital admission)
Trial population
Age ≥18 Confirmed diagnosis of autoimmune MG Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Dyspnea questionnaires
Dyspnea-12
Secondary outcomes
cardiopulmonary exercise test
cycle ergometer
Polysomnography
evaluation of sleep disordered breathing
Functional measures
6 minute walk test
Quality of life questionnaires
Revised version of the myasthenia gravis quality of life questionnaire (Burns, French validation Birnbaum)
Other outcomes
impact of myasthenia in daily living
impact of myasthenia in daily living score
Respiratory pressures
inspiratory and expiratory pressures
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Institut de Myologie, France
Lead sponsor
APHP
Collaborator